HER3 PET scan for advanced EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) with an EGFR mutation that cannot be treated with curative intent.
- You have had at least one EGFR inhibitor treatment (like osimertinib, gefitinib, or erlotinib) for your cancer.
- You have at least two tumors that are each at least 2 cm in size.
- You are willing to have a tumor biopsy (or provide a stored sample) for the study.
- You have no history of interstitial lung disease, severe lung problems, or untreated brain metastases.
- You are 18 or older, with good overall health and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET/CT scan to see how a radioactive tracer called Zr-trastuzumab collects in your lung cancer cells. The results will help doctors understand which patients with certain HER2 changes might benefit from HER2-targeted treatments.
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
This trial tests a new drug called patritumab deruxtecan for people with advanced solid tumors that have an NRG1 fusion. The drug targets a protein called HER3 on cancer cells and may help shrink tumors or slow their growth.
This trial is testing a new imaging probe that binds to EGFR mutations, which are common in some lung cancers. If you have lung cancer with a confirmed EGFR mutation, this scan may help doctors see your cancer more clearly.
Hear when a new EGFR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.